Resveratrol relieves ischemia-induced oxidative stress in the hippocampus by activating SIRT1

Experimental and Therapeutic Medicine

Volumn 10, Issue 2, 2015, Pages 525-530

  Meng, Zhuangzhi ^a   Li, Jianguo ^a   Zhao, Honglin ^a   Liu, Haiying ^a   Zhang, Guowei ^a   Wang, Lingzhan ^a   Hu, He ^a   Li, Di ^a   Liu, Mingjing ^a   Bi, Fulong ^a   Wang, Xiaoping ^a   Tian, Geng ^a   Liu, Qiang ^b   Buren, Batu ^a  

^a INNER MONGOLIA UNIVERSITY FOR NATIONALITIES   (China)

^b INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Brain ischemia; Hippocampus; Reactive oxygen species; Resveratrol; Sirtuin 1

Indexed keywords

REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REPERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUNEL ASSAY; WESTERN BLOTTING;

EID: 84931832756     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2555     Document Type: Article

References (43)

1. Feigin VL, Lawes CM, Bennett DA and Anderson CS: Stroke epidemiology: A review of population-based studies of incidence, prevalence and case-fatality in the late 20th century. Lancet Neurol 2: 43-53, 2003.
2. Green AR, Odergren T and Ashwood T: Animal models of stroke: Do they have value for discovering neuroprotective agents? Trend Pharmacol Sci 24: 402-408, 2003.
3. Xu SY and Pan SY: The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci Monit Basic Res 19: 37-45, 2013.
4. Moro MA, Almeida A, Bolanos JP and Lizasoain I: Mitochondrial respiratory chain and free radical generation in stroke. Free Radic Biol Med 39: 1291-1304, 2005.
5. Martin-Romero FJ, Garcia-Martin E and Gutierrez-Merino C: Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low-potassium-induced apoptosis of cerebellar granule cells. J Neurochem 82: 705-715, 2002.
6. Atlante A, Bobba A, Calissano P, Passarella S and Marra E: The apoptosis/necrosis transition in cerebellar granule cells depends on the mutual relationship of the antioxidant and the proteolytic systems which regulate ROS production and cytochrome c release enroute to death. J Neurochem 84: 960-971, 2003.
7. Li J, Wang Y, DU L, Xu C, Cao J, Wang Q, Liu Q and Fan F: Radiation-induced cytochrome c release and the neuroprotective effects of the pan-caspase inhibitor z-VAD-fmk in the hypoglossal nucleus. Exp Ther Med 7: 383-388, 2014.
8. Kleikers PW, Wingler K, Hermans JJ, Diebold I, Altenhöfer S, Radermacher KA, Janssen B, Görlach A and Schmidt HH: NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J Mol Med (Berl) 90: 1391-1406, 2012.
9. Zuo L and Motherwell MS: The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 532: 18-23, 2013.
10. Sochocka M, Koutsouraki ES, Gasiorowski K and Leszek J: Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: A new approach to therapy. CNS Neurol Disord Drug Targets 12: 870-881, 2013.
11. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR III, Bordone L, Guarente L and Krainc D: SIRT1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18: 159-165, 2011.
12. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S and Guarente L: SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci 32: 124-132, 2012.
13. Chong ZZ, Shang YC, Wang S and Maiese K: SIRT1: New avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets 16: 167-178, 2012.
14. Nakata R, Takahashi S and Inoue H: Recent advances in the study on resveratrol. Biol Pharm Bull 35: 273-279, 2012.
15. Gruber J, Tang SY and Halliwell B: Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann NY Acad Sci 1100: 530-542, 2007.
16. Pasinetti GM, Wang J, Marambaud P, Ferruzzi M, Gregor P, Knable LA and Ho L: Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp Neurol 232: 1-6, 2011.
17. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Mikolás E, Szijártó IA, Mérei A, Halmai R, Mészáros LG, et al: Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383-389, 2011.
18. Bradamante S, Barenghi L and Villa A: Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22: 169-188, 2004.
19. Pulsinelli WA, Brierley JB and Plum F: Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 11: 491-498, 1982.
20. Nikonenko AG, Radenovic L, Andjus PR and Skibo GG: Structural features of ischemic damage in the hippocampus. Anat Rec (Hoboken) 292: 1914-1921, 2009.
21. Li H, Zhang Y, Yu Y, Li B, Chen Y, Wu H, Wang J, Li J, Xiong X, He Q, Tian J, et al: Systemic revealing pharmacological signalling pathway networks in the hippocampus of ischaemia-reperfusion rats treated with baicalin. Evid Based Complement Alternat Med 2013: 630723, 2013.
22. Li J, Feng L, Xing Y, Wang Y, Du L, Xu C, Cao J, Wang Q, Fan S, Liu Q and Fan F: Radioprotective and Antioxidant effect of Resveratrol in Hippocampus by activating SIRT1. Int J Mol Sci 15: 5928-5939, 2014.
23. Kang Y, Jung WY, Lee H, Lee E, Kim A and Kim BH: Expression of SIRT1 and DBC1 in gastric adenocarcinoma. Korean J Pathol 46: 523-531, 2012.
24. Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, Matsuzaki T, Nishida K, Kurosaka M and Kuroda R: The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes. J Orthop Res 31: 531-537, 2013.
25. Chen F, Xu C, Du L, Wang Y, Cao J, Fu Y, Guo Y, Liu Q and Fan F: Tat-SmacN7 induces radiosensitization in cancer cells through the activation of caspases and induction of apoptosis. Int J Oncol 42: 985-992, 2013.
26. Fu Y, Wang Y, Du L, Xu C, Cao J, Fan T, Liu J, Su F, Fan S, Liu Q and Fan F. Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int J Mol Sci 14: 14105-14118, 2013.
27. Kitada M and Koya D: SIRT1 in Type 2 Diabetes: Mechanisms and therapeutic potential. Diabetes Metab J 37: 315-325, 2013.
28. Bernstein BE, Meissner A and Lander ES: The mammalian epigenome. Cell 128: 669-681, 2007.
29. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L and Reinberg D: SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 450: 440-444, 2007.
30. Nadtochiy SM, Redman E, Rahman I and Brookes PS: Lysine deacetylation in ischaemic preconditioning: The role of SIRT1. Cardiovasc Res 89: 643-649, 2011.
31. Shin SM, Cho IJ and Kim SG: Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly (ADP-ribose) polymerase-LKB1 pathway. Mol Pharmacol 76: 884-895, 2009.
32. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, Elmquist JK and Coppari R: Brain SIRT1: anatomical distribution and regulation byenergy availability. J Neurosci 28: 9989-9996, 2008.
33. + -dependent histone deacetylase SIRT1. J Biol Chem 282: 6823-6832, 2007.
34. Wassmann S, Wassmann K and Nickenig G: Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 44: 381-386, 2004.
35. Lu X, Ma L, Ruan L, Kong Y, Mou H, Zhang Z, Wang Z, Wang JM and Le Y: Resveratrol differentially modulates inf lammatory responses of microglia and ast rocytes. J Neuroinflammation 7: 46, 2010.
36. Terashvili M, Pratt PF, Gebremedhin D, Narayanan J and Harder DR: Reactive oxygen species cerebral autoregulation in health and disease. Pediatr Clin North Am 53: 1029-1037, 2006.
37. Zhang F, Liu J and Shi JS: Anti-inflammatory activities of resveratrol in the brain: Role of resveratrol in microglial activation. Eur J Pharmacol 636: 1-7, 2010.
38. Hu Y, Liu J, Wang J and Liu Q: The controversial links among calorie restriction, SIRT1 and resveratrol. Free Radic Biol Med 51: 250-256, 2011.
39. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, et al: Calorie restriction promotes mitochondrial biogenesis byinducing the expression of eNOS. Science 310: 314-317, 2005.
40. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006.
41. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, et al: Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 297: H13-H20, 2009.
42. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al: Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8: 157-168, 2008.
43. Lu X, Ma L, Ruan L, Kong Y, Mou H, Zhang Z, Wang Z, Wang JM and Le Y: Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7: 46, 2010.